Premium
Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer
Author(s) -
Hur Hoon,
Kim YoungBae,
Ham InHye,
Lee Dakeun
Publication year - 2015
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24043
Subject(s) - medicine , cancer , immunohistochemistry , gastroenterology , cancer research , oncology
Background Recent studies have demonstrated that acetyl‐CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined. Methods We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance. Results Among 350 GCs, 219 cases (62.6%) were classified as ACSS2‐low, whereas 131 cases (37.4%) were ACSS2‐high. Loss of ACSS2 expression (ACSS2‐low) was more frequently observed in undifferentiated histology ( P = 0.002), in cases with MLH1‐loss ( P = 0.003), and in cases with SIRT3‐low ( P < 0.001). The ACSS2‐low cases showed significantly lower mean disease‐free survival (DFS, 68.5 vs. 81.8 months; P = 0.025) and overall survival (OS, 73.5 vs. 86.6 months; P = 0.029). In multivariate analysis, loss of ACSS2 expression was identified as one of the independent prognostic factors predicting worse DFS (HR: 1.547, P = 0.018) and OS (HR: 1.476, P = 0.036). Conclusions We revealed that the loss of ACSS2 expression is a reliable independent poor prognostic factor in GC. Our results may expand our understanding of the involvement of glucose metabolism, including the role of ACSS2, in the pathogenesis of GC. J. Surg. Oncol. 2015;112:585–591 . © 2015 Wiley Periodicals, Inc.